SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer

Funding Rounds

▤ Summary

SciNeuro Pharmaceuticals closed a $53 million equity financing round led by LAV and ARCH Venture Partners, with participation from new and existing investors. The company also secured a $5 million non-dilutive research grant from The Michael J. Fox Foundation for Parkinsons Research. It will use the capital to advance its pipeline of therapies for neurodegenerative diseases, including programs targeting Lp-PLA21, beta amyloid, and LRRK22. SciNeuro also appointed Hogan Wan as chief financial officer to strengthen financial management, strategy, and operations as it moves into its next growth phase.

$ Funding

$
Amount $53.0M Total raised
□
Date December 4, 2025 Announcement date
◎
Investors ARCH Venture Partners Lead investors
▥
Company https://scineuro.com Funded company

▥ Classifications

industries
No industries detected
applications
Accounting and Taxes

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies